Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Suspended 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 20NIH 3INDUSTRY 3OTHER_GOV 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 14Sarcoma 12Thoracic 5Gastrointestinal 5Gynecologic 3Dermatologic 3Breast 3Head & Neck 2Other solid neoplasm 1Genitourinary 1Endocrine 1

Conditions

Skin Neoplasms 1Melanoma 1Eyelid Squamous Cell Carcinoma 1

Interventions

aldesleukin 69Cyclophosphamide 50fludarabine phosphate 36fludarabine 30Interleukin-2 27incomplete Freund's adjuvant 22Ipilimumab 20Biopsy 20Specimen Handling 19Magnetic Resonance Spectroscopy 19MART-1 Antigen 15CTLA-4 Antigen 15sargramostim 14Nivolumab 13Filgrastim 13montanide ISA 51 12Sorafenib 12Interferon-alpha 11pembrolizumab 10trametinib 9Temozolomide 9Bevacizumab 9dabrafenib 8temsirolimus 7Sirolimus 7Gene Expression Profiling 7tanespimycin 6Paclitaxel 6Dacarbazine 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Surgical Procedures, Operative × Dermatologic × Clear all
NCT04708418 2026-05-14

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
60 enrolled
Dermatologic

Melanoma

NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT00126555 2019-08-30

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 12 charts
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡